BetterScholar BetterScholar

J. Petkau

Neurology, Annals of Neurology, Brain : a journal of neurology, Journal of the American Medical Association, Lancet Neurology, American Journal of Respiratory and Critical Care Medicine, Environmental Health Perspectives, American Journal of Epidemiology, Nature Reviews Neurology Show more
12
Role
Title
Level Year L/R
🐜 Defining the clinical course of multiple sclerosis
32 auth. F. Lublin, S. Reingold, Jeffrey A. Cohen, G. Cutter, P. SΓΈrensen, A. Thompson, J. Wolinsky, L. Balcer, B. Banwell, F. Barkhof, B. Bebo, P. Calabresi, M. Clanet, G. Comi, R. Fox, ... M. Freedman, A. Goodman, M. Inglese, L. Kappos, B. Kieseier, J. Lincoln, C. Lubetzki, Aaron E Miller, X. Montalban, P. O'Connor, J. Petkau, C. Pozzilli, R. Rudick, M. Sormani, O. StΓΌve, E. Waubant, C. Polman 		11 2014
11
🐜
🐜 Development of a multiple sclerosis functional composite as a clinical trial outcome measure.
17 auth. G. Cutter, M. Baier, R. Rudick, D. Cookfair, J. Fischer, J. Petkau, K. Syndulko, B. Weinshenker, J. Antel, C. Confavreux, ... G. Ellison, F. Lublin, Aaron Miller, Stephen M. Rao, S. Reingold, A. Thompson, E. Willoughby 		10 1999
10
🐜
🐜 Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
16 auth. R. Rudick, J. Antel, C. Confavreux, G. Cutter, G. Ellison, J. Fischer, F. Lublin, Aaron Miller, J. Petkau, S. Rao, ... S. Reingold, K. Syndulko, Alan Thompson, Joy Wallenberg, B. Weinshenker, E. Willoughby 		8 1997
8
🐜
🐜 Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
10 auth. A. Shirani, Yinshan Zhao, M. E. Karim, C. Evans, E. Kingwell, M. L. van der Kop, ... J. Oger, P. Gustafson, J. Petkau, H. Tremlett 		8 2012
8
🐜
🐜 MRI T2 lesion burden in multiple sclerosis
12 auth. David K. B. Li, Ulrike Held, J. Petkau, M. Daumer, F. Barkhof, F. Fazekas, ... Joseph A. Frank, L. Kappos, David H. Miller, J. Simon, J. Wolinsky, M. Filippi 		7 2006
7
🐜
🐜 Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
15 auth. C. Polman, A. Bertolotto, F. Deisenhammer, G. Giovannoni, H. Hartung, B. Hemmer, J. Killestein, H. McFarland, J. Oger, A. Pachner, ... J. Petkau, A. Reder, S. Reingold, H. Schellekens, P. SΓΈrensen 		7 2010
7
🐜
🐜 Clinical outcomes assessment in multiple sclerosis
16 auth. R. Rudick, J. Fischer, J. Antel, C. Confavreux, G. Cutter, G. Ellison, F. Lublin, Aaron Miller, J. Petkau, Stephen M. Rao, ... S. Reingold, K. Syndulko, A. Thompson, Joy Wallenberg, B. Weinshenker, E. Willoughby 		7 1996
7
🐜
🐬 Acute effects of ambient inhalable particles in asthmatic and nonasthmatic children.
S. Vedal, J. Petkau, R. White, J. Blair 		7 1998
7
🐬
🐒 Air pollution and daily mortality in a city with low levels of pollution.
S. Vedal, M. Brauer, R. White, J. Petkau 		7 2003
7
🐒
🐜 Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b
9 auth. C. Polman, L. Kappos, R. White, F. Dahlke, K. Beckmann, C. Pozzilli, ... A. Thompson, J. Petkau, D. Miller 		6 2003
6
🐜
🐬 Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.
M. E. Karim, P. Gustafson, J. Petkau, H. Tremlett 		6 2016
6
🐬
🐜 MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials
15 auth. F. Barkhof, J. Simon, F. Fazekas, M. Rovaris, L. Kappos, N. Stefano, C. Polman, J. Petkau, E. Radue, M. Sormani, ... David K.B. Li, P. O'Connor, X. Montalban, David H. Miller, M. Filippi 		6 2012
6
🐜